2024 Asthma Capitals Report
Asthma Capitals™ Report Drives Policy Change Agenda
08 oct. 2024 08h19 HE | Asthma and Allergy Foundation of America
Washington, DC, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America’s (AAFA) 2024 Asthma Capitals™ report highlights the most challenging cities for people with asthma....
Monaghan Medical Headquarters in Plattsburgh with 2024 Zenith Award logo and 'For outstanding contributions in the respiratory care profession' text
Monaghan Medical Wins 2024 AARC Zenith Award
03 oct. 2024 04h00 HE | Monaghan Medical Corporation
Monaghan Medical Corporation has been honored with the prestigious 2024 Zenith Award from the American Association for Respiratory Care (AARC). This award
2024 Asthma Capitals
Report Names Most Challenging Cities for Living with Asthma in 2024
10 sept. 2024 07h00 HE | Asthma and Allergy Foundation of America
Washington, DC, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Today, the Asthma and Allergy Foundation of America (AAFA) released its 2024 Asthma Capitals™ report highlighting the most challenging cities for...
Upstream_Logo_CMYK.png
Upstream Bio Announces Oral Presentation of New Data from a Phase 1b Multiple Ascending Dose Trial of Verekitug (UPB-101) in Adults with Asthma at the European Respiratory Society Congress
09 sept. 2024 08h00 HE | Upstream Bio, Inc.
Upstream gives oral presentation of clinical data for verekitug in patients with severe asthma at European Respiratory Society congress
Regeneron Logo.jpg
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
26 août 2024 01h00 HE | Regeneron Pharmaceuticals, Inc.
20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) Data from...
September Asthma Peak
Warning: September Asthma Spike Ahead
22 août 2024 07h00 HE | Asthma and Allergy Foundation of America
Washington, DC, Aug. 22, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) today warned about a combination of factors coming together to make September the worst month of...
Acute Respiratory Distress Syndrome Market
Acute Respiratory Distress Syndrome Analysis Report 2024: A $2.36 Billion Market by 2032 from $1.23 Billion in 2023
18 juil. 2024 06h27 HE | Research and Markets
Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome Market Report by Type, End User, Regions and Company Analysis 2024-2032" report has been added to ...
22157.jpg
Bronchiectasis Opportunity Assessment and 10 Year Forecast 2023-2033
06 juin 2024 09h09 HE | Research and Markets
Dublin, June 06, 2024 (GLOBE NEWSWIRE) -- The "Bronchiectasis: Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering. This report covers the 8 Major...
Upstream_Logo_CMYK.png
Upstream Bio Presents Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society International Conference
22 mai 2024 11h15 HE | Upstream Bio, Inc.
Positive results from a Phase 1 dose ranging study of verekitug (UPB-101) in asthma presented at ATS 2024
Upstream_Logo_CMYK.png
Upstream Bio to Present Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society (ATS) International Conference
15 mai 2024 07h00 HE | Upstream Bio, Inc.
Upstream Bio will present clinical data from dose-ranging study of verekitug (UPB-101) in adults with asthma at the American Thoracic Society conference